Tenon Medical, Inc. (TNON)
CIK 1560293 · all EDGAR filings →
Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.
Shares outstanding over time
Latest: 667,047 shares as of Aug 13, 2026 (10-Q).⊙
Cash runway
Going-concern warning
auditor flagged substantial doubt
The company itself flagged going-concern doubt in a filing.
Full breakdown: cash runway tool
Warrants
| Tranche | Warrants | Exercise price | Term | Notes |
|---|---|---|---|---|
| Warrant | 378,948 | $0.035 | — | — |
| Series C1 Warrants | 69,878 | $43.75 | 5y | — |
| PIPE Warrants | 63,369 | $40.6 | 3y | — |
| Series E Warrants | 36,329 | $70 | — | — |
| New Warrants | 34,939 | $43.75 | — | — |
| Series C2 Warrants | 34,939 | $43.75 | 3y | — |
| Series D Warrants | 20,958 | $70 | — | — |
| Registered Offering Warrants | 5,929 | not tagged | — | — |
| Series A Preferred Stock Warrants | 1,484 | $149.8 | — | — |
| Series B Preferred Stock Warrants | 464 | $149.65 | — | — |
| Convertible Note Warrants | 161 | $543.2 | — | — |
| IPO Warrants | 35 | $14000 | — | — |
Tranches exactly as the company dimensioned them in its 10-Q filed Aug 13, 2026 →. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.
Warrants outstanding: 20.0M underlying shares, as reported Jun 30, 2023 (10-Q).
Reported exercise price: $1.16 (aggregate figure as tagged; individual tranches vary).
Rough fully diluted estimate: 20.7M = 667,047 O/S + 20.0M warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.
Convertible notes
| Note | Principal | Carrying | Conv. price | Rate | If converted |
|---|---|---|---|---|---|
| Convertible Promissory Notes | not tagged | $5.2M | $5.4845 | — | — |
Notes exactly as the company dimensioned them in its 10-Q filed Aug 13, 2026 →. Principal is face amount as tagged, not what remains after repurchases unless the filer updated the tag. A note the filer did not dimension is absent here, not absent from the balance sheet; the exhibits stay the ground truth.
Fully diluted build-up
Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.
| Shares outstanding | 667,047 | Aug 13, 2026 |
| + Warrant (if exercised) | 378,948 | Jul 1, 2026 |
| + Series C1 Warrants (if exercised) | 69,878 | Mar 11, 2025 |
| + PIPE Warrants (if exercised) | 63,369 | Nov 11, 2025 |
| + Series E Warrants (if exercised) | 36,329 | Mar 25, 2025 |
| + New Warrants (if exercised) | 34,939 | Mar 11, 2025 |
| + Series C2 Warrants (if exercised) | 34,939 | Mar 11, 2025 |
| + Series D Warrants (if exercised) | 20,958 | Mar 25, 2025 |
| + Registered Offering Warrants (if exercised) | 5,929 | Jun 30, 2026 |
| + Series A Preferred Stock Warrants (if exercised) | 1,484 | Feb 20, 2024 |
| + Series B Preferred Stock Warrants (if exercised) | 464 | Sep 5, 2024 |
| + Convertible Note Warrants (if exercised) | 161 | Nov 30, 2023 |
| + IPO Warrants (if exercised) | 35 | Apr 30, 2022 |
| Fully diluted estimate | 1.3M | +97.1% vs O/S |
Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.
Registrations and offerings
Registered offering capacity on live registrations: $112.6Mfrom the structured fee exhibits; registered is not remaining, takedowns are not subtracted
Last 12 months: 6 executed · 9 registered.
Full history and shelf status: offering checker · S-3 shelf checker
Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.
Keep going: float checker · offering calendar · short-squeeze screener · full TNON workspace